The Directorate General of Drug Administration (DGDA) has issued an urgent letter instructing hospitals across Bangladesh to implement the newly revised prices of coronary stents used in heart treatment. The directive, sent on Tuesday, includes four mandatory instructions for hospitals, emphasizing that the new maximum retail prices (MRP) must be displayed publicly and strictly followed in all sales.
According to the DGDA, the price revision was made under the guidance of the Ministry of Health and Family Welfare and based on recommendations from the expert advisory committee. The new prices were determined considering taxes, VAT, commissions, and reasonable profit margins for importers. The final approval came after the committee’s seventh meeting on May 13, which reviewed appeals from several importing firms.
The DGDA stated that prices for imported stents now range from Tk 1,000 to Tk 47,800, with significant reductions for specific models such as the “Silin Covered Stent” and “Magma Rapamycin” stents. The directive follows earlier complaints that some hospitals continued selling stents at old rates despite a February 25 notification reducing prices by 5–19 percent.
স্টাফ রিপোর্টার প্রকাশ : ০৯ জুন ২০২৬, ১৮: ৪৫ হৃদরোগের চিকিৎসায় ব্যবহৃত হার্টের রিং বা করোনারি স্টেন্টের (স্টেন্ট) পুনঃনির্ধারিত মূল্য বাস্তবায়নে দেশের হাসপাতালগুলোকে চিঠি দিয়েছে ঔষধ প্রশাসন অধিদপ্তর (ডিজিডিএ)। চিঠিতে হাসপাতালগুলোর জন্য ৪টি জরুরি নির্
The ‘1 Nojor’ media platform is now live in beta, inviting users to explore and provide feedback as we continue to refine the experience.
